Zhaohui Xu

This body of work spans several distinct medical research areas, most prominently the development and preclinical testing of antibody-drug conjugates (ADCs, drugs that combine a targeting antibody with a toxic payload) for osteosarcoma, a bone cancer, including work on the target protein CADM1 and B7-H3. Other publications touch on tumor immunology (e.g., regulatory T cells and macrophages in ovarian cancer, hepatitis C immune responses), cancer metastasis biology, and unrelated topics such as chemical synthesis methods and object detection algorithms, suggesting contributions to multiple collaborative projects rather than a single narrow focus. The name-associated record appears to aggregate work from different research contexts, so the underlying research identity may represent contributions across cancer biology, immunology, and other fields.

Publication output has grown over the last decade, rising from single digits in 2017-2019 to a peak in 2022, with continued substantial activity through 2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026